Current Continuous Process Validation Program

Another eight medications already authorized in the EU were recommended for extensions of various indications.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.